Abbott Issues Full-year 2024 Guidance For Adjusted EPS Of $4.50 To $4.70 Versus Consensus Of $4.64
Portfolio Pulse from Benzinga Newsdesk
Abbott Laboratories has provided its full-year 2024 earnings guidance, projecting an adjusted EPS of $4.50 to $4.70. This forecast is in line with the consensus estimate of $4.64.
January 24, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Abbott Laboratories anticipates an adjusted EPS of $4.50 to $4.70 for the full year of 2024, which aligns with market expectations.
Abbott's guidance is in line with consensus estimates, which suggests that the market has already anticipated this performance level. Therefore, the short-term impact on the stock price is likely to be neutral, as there are no positive or negative surprises.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100